• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Scientists create enhanced method to identify strongest cancer-fighting immune cells

Bioengineer by Bioengineer
July 9, 2026
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A team of researchers at The University of Texas MD Anderson Cancer Center has developed an innovative microfluidic platform named ATTACH (Assessment of T cells Tethered to Antigen Class I Histocompatibility) that enhances the isolation of rare tumor-reactive T cells—immune cells capable of recognizing and attacking cancer cells. This breakthrough addresses a critical obstacle in immunotherapy development by enabling rapid and reliable identification of highly effective cancer-targeting T cells without prior knowledge of tumor antigens.

Tumor-reactive T cells represent a small subset within the often densely infiltrated tumor microenvironment. These cells can specifically detect cancer-specific antigens—unique proteins expressed on tumor cells—and execute immune responses to eradicate malignancies. However, given the heterogeneity and mutability of tumors, antigens vary widely even within a single tumor, complicating the selection of appropriate T cells for therapeutic use. Conventional approaches depend on knowing specific antigens in advance, limiting their utility and efficiency.

The ATTACH platform circumvents this limitation by exploiting the tumor itself as a presentation source for natural, native cancer antigens. By co-incubating T cells derived from tumors with live cancer cells under controlled microfluidic conditions, the platform measures the avidity—or binding strength—between them. Gentle fluid flows then wash away T cells with weaker or non-specific interactions, enriching for the most avid and thus potentially most tumor-reactive T cells. This selective process significantly boosts the yield of cancer-specific T cells, reportedly increasing their relative proportion up to tenfold even when starting with extremely rare populations.

Importantly, ATTACH maintains the functional integrity of isolated T cells, preserving their tumor-killing capabilities without requiring specialized instrumentation commonly associated with such isolations. This user-friendly, scalable technology offers a robust tool for both basic research and clinical applications, potentially accelerating the creation of personalized immunotherapies tailored to an individual’s unique tumor profile.

The research, led by Dr. Alexandre Reuben and collaborators at MD Anderson, was published in the Journal for ImmunoTherapy of Cancer. It highlights how harnessing intrinsic cell-to-cell interactions can unlock new avenues for immune precision medicine. By allowing direct identification of effective T cells without the constraints of predefined antigen knowledge, ATTACH paves the way for next-generation immunotherapies with improved specificity and efficacy.

This advancement comes at a critical time when cancer immunotherapy continues to revolutionize treatment paradigms, yet faces challenges in isolating potent tumor-reactive lymphocytes. ATTACH offers a promising strategy to overcome these bottlenecks, potentially translating into faster development timelines and better patient outcomes. The platform’s reliance on biophysical properties of immune-cancer cell binding rather than genetic or molecular markers marks a novel direction in cancer immunology technology.

By providing an adaptable framework to enrich rare, therapeutically valuable immune cells directly from tumors, ATTACH could significantly impact both research and clinical workflows. The ability to readily capture the “best-fit” T cells might enhance the effectiveness of adoptive cell therapies and inform the design of vaccines and combination treatments, reinforcing the arsenal against cancer.

Subject of Research: Tumor-reactive T cell isolation and cancer immunotherapy development
Article Title: Information not provided
News Publication Date: July 8, 2026
Web References: https://jitc.bmj.com/content/14/7/e014960
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: Cancer immunology, Tumor-reactive T cells, Immunotherapy, Microfluidics, Immune response, Antigens

Tags: advances in T cell therapy developmentcancer immunotherapyidentification of cancer-specific antigensimmune cell-based cancer therapiesinnovative cancer treatment methodsmicrofluidic platform for cancer detectionpersonalized cancer immunotherapyrapid detection of anti-cancer immune cellsT cell avidity measurementtargeting heterogenous tumor antigenstumor microenvironment analysistumor-reactive T cell isolation

Share12Tweet7Share2ShareShareShare1

Related Posts

Lobectomy Attenuates Adverse Impact of STAS in Stage IA Lung Adenocarcinoma

Lobectomy Attenuates Adverse Impact of STAS in Stage IA Lung Adenocarcinoma

November 16, 2026
Limiting Lymph Node Dissection May Not Be Inherently Safer in Palliative Gastrectomy

Limiting Lymph Node Dissection May Not Be Inherently Safer in Palliative Gastrectomy

November 16, 2026

Centralized Chordoma Care Linked to Better Survival and Notable Access Disparities

November 16, 2026

Chemotherapy Neuropathy Symptoms Persist in Most Breast Cancer Patients Years Later

November 16, 2026

POPULAR NEWS

  • Taxonomic Study Restores Tenumembrana fallax and Names Two Cockroach Species

    Taxonomic Study Restores Tenumembrana fallax and Names Two Cockroach Species

    29 shares
    Share 12 Tweet 7
  • Vertebrobasilar Dolichoectasia Linked to Cognitive Impairment After Acute Ischemic Stroke

    29 shares
    Share 12 Tweet 7
  • Healthcare Professionals Favor Hybrid Formats for Geriatric Education in Multinational Survey

    29 shares
    Share 12 Tweet 7
  • Three New Species of Wood-Decaying Fungi Identified in Chinese Forests

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Blockchain-Integrated Machine Learning Enhances Fraud Detection in Supply Chain Networks

Dynamic Cognitive Models Improve External Dementia Transition Predictions But Face Major Limits

Binary Hippopotamus Optimization Achieves High Accuracy Across Sixteen Cancer Datasets

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.